Dr Bjorn Nilsson, most recently from Biacore and earlier CEO of Karo Bio, has been recruited as Head of Corporate Development and will be responsible for Biovitrum's complete commercial and scientific business development. All persons here mentioned will be reporting directly to CEO Mats Pettersson and will be part of the Biovitrum Management Team.
The Biovitrum Management Team also comprises Hans Orstrom, Head of Biopharmaceuticals and Marketing & Sales, Goran Arvidson, Chief Financial Officer, Fredrik Berg, General Counsel, Anna Karin Kallen, Head of Corporate Communications and Maria Berggren, Head of Human Resources.
The new organisation will commence January 1st 2007.
About Biovitrum
Biovitrum is one of the largest biopharma companies in Europe. With operations in Sweden and in the UK Biovitrum conducts research and develops pharmaceuticals for unmet medical needs both for common diseases and conditions that affect smaller patient populations. Biovitrum has a broad and balanced R&D portfolio with several projects in clinical and preclinical phases for the treatment of obesity, diabetes, inflammation and eye and blood diseases as well as a number of well defined niche indications. Biovitrum develops and produces protein-based drugs on a contractual basis and markets a range of specialist pharmaceuticals primarily in the Nordic countries. Biovitrum has approximately revenues of USD 119 million and 550 employees. Biovitrum is listed on the Stockholm Stock Exchange since September 15, 2006. For more information see www.biovitrum.com
This information was brought to you by Waymaker http://www.waymaker.net
© 2006 Business Wire
